Forum Topic News
  • Conversation: Anavex sets up trial of ‘triple-action’ Alzheimer’s drug

    • July 4, 2018 12:39 PM BST
      • Post(s)

      Anavex sets up trial of ‘triple-action’ Alzheimer’s drug

      US biotech Anavex has been cleared to start a phase IIb/III trial of an Alzheimer’s drug that is designed to tackle three features of the disease – amyloid, tau and inflammation.
      The company is hoping that by tackling all three characteristics linked to the pathology of Alzheimer’s it may be able to succeed where dozens of other trials – mainly looking at blocking the formation of amyloid deposits in the brain – have failed.
      Anavex’ candidate is Anavex 2-73, a sigma-1 receptor (S1R) transmembrane protein activator that is thought to be involved in regulating homeostasis in cells, keeping them in a healthy, steady state by reducing factors such as oxidative stress, protein misfolding, mitochondrial dysfunction and inflammation – all of which are seen in the brains of Alzheimer’s patients.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel